Primaquine

證據等級: L5

預測適應症: 8 個

Primaquine: From Malaria to Pneumocystis Pneumonia (PCP)

One-Sentence Summary

Primaquine is the only globally available 8-aminoquinoline antimalarial, licensed since 1952 as the standard treatment for Plasmodium vivax radical cure (eliminating dormant liver-stage hypnozoites) and for blocking P. falciparum transmission to mosquitoes — yet it remains entirely unregistered in the Philippines.

The TxGNN model identifies Pneumocystis Pneumonia (PCP / Pneumocystosis) as a clinically supported new indication, backed by 2 completed randomized controlled trials and 20+ publications at Evidence Level L1; it simultaneously confirms the established malaria indication with over 50 clinical trials and 20 publications at Evidence Level L1.

⚠️ Model Signal Caveat: The four highest TxGNN prediction scores in this dataset all point to myiasis variants (fly-larva infestation, scores 0.9972–0.9975). These are assessed as knowledge-graph false positives — myiasis is caused by arthropod larvae with no pharmacological overlap with Primaquine’s antiprotozoal mechanism, and zero supporting clinical or preclinical evidence exists. The identical scores across three myiasis subtypes confirm topology-driven artifacts rather than genuine biological signals. This report focuses on the two clinically meaningful L1-supported indications: malaria and pneumocystosis.

Quick Overview

Item	Content
Original Indication	Malaria — P. vivax radical cure (hypnozoite eradication) and P. falciparum gametocytocidal therapy
Predicted New Indication	Pneumocystosis (Pneumocystis jirovecii Pneumonia, PCP)
TxGNN Prediction Score	99.32% (PCP, rank 2956) · 99.38% (Malaria, rank 4495)
Evidence Level	L1 (≥ 2 completed Phase 3 RCTs across both indications)
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Primaquine is metabolized primarily by hepatic CYP2D6 into reactive oxidative intermediates — particularly 5-hydroxyprimaquine and downstream quinone-imine species. These metabolites disrupt mitochondrial electron transport chains and generate intracellular oxidative stress lethal to susceptible organisms. This is the same mechanism that eliminates P. vivax hypnozoites in the liver and sterilizes P. falciparum gametocytes in the blood — and it forms the mechanistic basis for activity against organisms sharing similar mitochondrial architecture.

Pneumocystis jirovecii, despite its phylogenetic reclassification as a fungus, retains a mitochondrial electron transport chain structurally distinct from that of typical pathogenic fungi such as Candida or Aspergillus, and instead resembles the protozoan-like primitive eukaryote structure targeted by primaquine metabolites. Clinically, the Clindamycin + Primaquine combination exploits a synergistic dual mechanism: Clindamycin inhibits P. jirovecii ribosomal protein synthesis, while primaquine’s oxidative metabolites disrupt mitochondrial respiration — together achieving rapid clearance of both trophozoites and cysts. This combination has been in active clinical use since its foundational in vitro description in 1988 (Queener et al.), and is now formally listed in ECIL guidelines as a recognized second-line therapy for PCP in non-HIV haematology patients, and as a standard alternative when TMP-SMX is contraindicated or not tolerated in HIV/AIDS patients.

Regarding malaria: Primaquine’s role is well-established beyond any doubt. It remains the only available drug capable of clearing P. vivax and P. ovale hypnozoites (preventing relapse), and the only potent gametocytocide for P. falciparum (blocking transmission). Its absence from the Philippines formulary represents a critical gap — NCT04222088 documents its active use in Palawan Province, confirming local clinical relevance. The TxGNN model’s prediction of malaria at rank 7 effectively serves as a validation signal: the drug belongs in the Philippines antimalarial toolkit.

Clinical Trial Evidence — Malaria (Rank 7 · L1)

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02787070	Phase 4	Completed	420	TRIPI trial — Randomized controlled trial of Primaquine radical cure for P. vivax in Papua, Indonesia; core RCT establishing hypnozoite eradication efficacy
NCT01640574	Phase 3	Completed	680	Southeast Asia: randomized comparison of 7-day vs 14-day Primaquine combined with DHP or chloroquine for P. vivax radical cure
NCT02216123	Phase 3	Completed	251	DETECTIVE trial — Double-blind RCT of Tafenoquine vs Primaquine (active comparator) for P. vivax, formally establishing Primaquine as the reference standard
NCT01838902	Phase 3	Completed	467	Gametocytocidal efficacy of Primaquine in P. falciparum asymptomatic carriers in The Gambia; dose-optimization for transmission blocking
NCT05690841	Phase 3	Recruiting	7,530	FLAME trial — Large cluster-RCT of focal mass drug administration including Primaquine for P. vivax elimination in Peru; highest-powered current design
NCT03773536	Phase 4	Completed	146	ASAQ + single low-dose Primaquine (0.25 mg/kg) for uncomplicated P. falciparum in Zanzibar; confirms transmission-blocking dose in Africa
NCT02434952	Phase 4	Completed	109	Low-dose Primaquine (0.25 mg/kg) for P. falciparum transmission blocking in symptomatic Cambodians; tolerability and safety
NCT04222088	N/A	Completed	159	Philippines-specific (Palawan) — Antimalarial efficacy trial in Bataraza, Brookes, and Rizal; Primaquine used at 0.75 mg base/kg for P. vivax
NCT04864444	N/A	Completed	10,715	Cluster-RCT of mass drug administration (DHA-PPQ + single low-dose Primaquine) in Senegal for P. falciparum seasonal malaria control
NCT05540470	N/A	Completed	1,991	Real-world P. vivax radical cure in highly mobile mining populations across the Guiana Shield; pragmatic implementation evidence

Clinical Trial Evidence — Pneumocystosis / PCP (Rank 8 · L1)

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00000640	Phase 3	Completed	290	Core Phase 3 RCT: Clindamycin/Primaquine vs Dapsone/TMP vs TMP-SMX for mild–moderate PCP in AIDS patients; established Clindamycin/Primaquine as an effective alternative with comparable efficacy
NCT00000717	N/A	Completed	50	Pivotal early trial: Safety and efficacy of Clindamycin + Primaquine for mild–moderate P. carinii pneumonia in AIDS patients; 91% clinical response rate reported
NCT07357103	Phase 4	Not Yet Recruiting	416	SPIRIT-PCP Platform — Modern large-scale adaptive trial positioning second-line PCP therapies (including Clindamycin/Primaquine) for TMP-SMX-intolerant patients; expected to generate high-quality contemporary evidence
NCT04328688	N/A	Completed	30	PCP treatment comparison after solid organ transplantation; Clindamycin/Primaquine evaluated as second-line alternative in non-HIV immunocompromised setting
NCT06691321	N/A	Recruiting	60	Caspofungin efficacy for PCP in HIV/AIDS patients; Primaquine-based standard regimen serves as clinical comparator reference

Literature Evidence — Malaria

PMID	Year	Type	Journal	Key Findings
24499628	2013	Meta-analysis	Parasites & Vectors	Systematic review and meta-analysis: artemisinin derivatives + Primaquine block P. falciparum transmission to mosquitoes; quantifies gametocytocidal benefit
40813102	2025	Systematic Review	BMJ Global Health	Single low-dose Primaquine (SLDPQ) for malaria control in Africa: safety, efficacy, and implementation barriers; latest evidence synthesis
35353968	2022	Clinical Study	NEJM	Primaquine and P. vivax malaria recurrence in Brazil; clinical cohort documenting efficacy and emerging resistance surveillance
22152065	2011	Review	Malaria Journal	Comprehensive update on Primaquine in vivax malaria: efficacy evidence, G6PD hazards, resistance data, and management guidance
25363455	2014	Review	Malaria Journal	“Primaquine: the risks and the benefits” — authoritative review covering G6PD hemolysis, dosing, and global policy implications
29672516	2018	Policy Review	PLoS NTD	Divergent Primaquine policies across 77 malaria-endemic countries; G6PD testing practice gaps and recommendations
40867022	2025	Pharmacogenomics	Emerging Infect Dis	CYP2D6 genotype and Primaquine treatment outcomes in Venezuela; ≈25% intermediate/poor metabolizers with increased vivax recurrence
27039396	2016	Review	BMC Medicine	Low-dose Primaquine + ACT for P. falciparum transmission reduction: clinical promise vs hemolysis risk framing
28417346	2017	Review	Bull Soc Pathol Exot	Role of Primaquine in malaria control and elimination in French-speaking Africa; underutilization analysis and MOA summary
15494911	2004	Review	Clin Infect Dis	“Primaquine therapy for malaria” — comprehensive review of 1946–2004 clinical applications; defines spectrum of evidence

Literature Evidence — Pneumocystosis / PCP

PMID	Year	Type	Journal	Key Findings
39732393	2025	Systematic Review / Network Meta-analysis	Clin Microbiol Infect	Network meta-analysis of all PCP treatment RCTs in HIV patients; quantifies Clindamycin/Primaquine efficacy and safety relative to TMP-SMX and other regimens
27550993	2016	Clinical Guideline (ECIL)	J Antimicrob Chemother	ECIL guidelines for PCP in non-HIV haematology patients; Clindamycin + Primaquine formally listed as second-line treatment option
9770152	1998	RCT	Clin Infect Dis	CTN 004: Multicenter double-blind RCT (n=87) — Clindamycin/Primaquine vs TMP-SMX for AIDS-related PCP; comparable overall efficacy confirmed
2060532	1991	Clinical Trial (Phase 2)	Eur J Clin Microbiol	Clindamycin + Primaquine primary treatment for mild–moderate P. carinii pneumonia; 91% clinical response in 36 AIDS patients
8086551	1994	Clinical Study	Clin Infect Dis	ACTG 044: Multi-center study of Clindamycin/Primaquine for mild–moderate PCP; systematic safety and efficacy data
3261959	1988	In vitro / In vivo	Antimicrob Agents Chemother	Foundational preclinical study: Clindamycin + Primaquine activity against P. carinii in vitro and in animal models; establishes synergistic mechanism
33870843	2021	Review	Expert Opin Pharmacother	PCP prevention and treatment overview; Clindamycin/Primaquine positioned as second-line in both HIV and non-HIV immunocompromised populations
36969352	2023	Review	Avicenna J Med	PCP management in HIV and non-HIV immunocompromised; discusses rising non-HIV incidence and expanding role of alternative regimens
36160421	2022	Review	Front Pharmacol	PCP treatment in G6PD-deficient patients; Primaquine-specific risk assessment and monitoring strategies for co-occurring G6PD deficiency
18971152	2008	Review	J Formos Med Assoc	Pneumocystis pneumonia review with Asia-Pacific perspective; regionally relevant for Philippines clinical context

Philippines Market Information

Primaquine currently has no registered pharmaceutical products in the Philippines. The FDA Philippines has issued zero product licenses, and no approved indications, dosage forms, or marketing authorizations exist in the national database.

This absence is clinically significant: Primaquine is designated a WHO Essential Medicine (23rd edition), and clinical evidence demonstrates active use in Philippine territory. The trial NCT04222088 specifically documented Primaquine administration at 0.75 mg base/kg for P. vivax in Palawan Province (Bataraza, Brookes Point, Rizal municipalities), confirming real-world demand with no formal regulatory framework currently in place.

Safety Considerations

Full package insert warnings and contraindications were not available in the current Evidence Pack. The following safety information is well-established in published literature:

Key Warnings:

G6PD Deficiency-Induced Hemolytic Anemia: The most critical safety risk. Primaquine oxidative metabolites cause acute, potentially life-threatening hemolytic anemia in glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals. G6PD gene deficiency frequencies of 3–30% are documented in malaria-endemic Southeast Asian and Pacific populations. Quantitative G6PD testing (e.g., CareStart™ RDT, demonstrated feasible in NCT02876549) is mandatory before Primaquine administration under all current WHO guidelines.
Methemoglobinemia: Dose-dependent formation reported, particularly at higher doses; hemoglobin and methemoglobin monitoring required.
CYP2D6 Pharmacogenomics and Treatment Failure: Approximately 25% of patients may be CYP2D6 intermediate or poor metabolizers (PMID 40867022), generating insufficient active metabolite and experiencing P. vivax relapse despite full compliance. CYP2D6 genotyping is emerging as a clinical consideration in high-recurrence settings.

Drug Interactions: No DDI data was retrieved for this Evidence Pack. Based on published pharmacology, co-administration with other oxidizing agents (dapsone, sulfonamides, nitrofurantoin) may potentiate hemolytic risk. Quinolone antimalarials (quinine, chloroquine) may interact pharmacokinetically via shared metabolic pathways.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Primaquine holds exceptional, multi-level clinical evidence for two indications directly relevant to the Philippines: (1) Malaria — it is the only WHO-recommended drug for P. vivax radical cure, with evidence from dozens of Phase 3–4 RCTs across Southeast Asia and documented use in Palawan; (2) Pneumocystosis (PCP) — Phase 3 RCT data and multiple clinical guidelines support Clindamycin + Primaquine as a validated second-line regimen for immunocompromised patients intolerant to TMP-SMX. The complete absence of Philippines registration for a WHO Essential Medicine with this evidence base warrants urgent regulatory attention.

To proceed, the following is needed:

G6PD screening infrastructure: Implement point-of-care G6PD testing (quantitative RDT) at all malaria treatment facilities and pharmacies before dispensing; train healthcare workers on interpretation and dose-adjustment protocols for deficient patients
Full prescribing information: Obtain and review complete FDA Philippines-equivalent package insert or WHO prescribing information; resolve current data gaps on formal contraindications and approved warnings
CYP2D6 pharmacogenomics plan: Consider population-level CYP2D6 screening or empirical dose-adjustment protocols for P. vivax radical cure to address the ≈25% intermediate/poor metabolizer rate identified in regional studies
Philippines epidemiology data: Quantify local G6PD deficiency prevalence in Palawan and other malaria-endemic provinces to calibrate hemolytic risk estimates; review NCT04222088 safety outcomes
FDA Philippines registration pathway: Initiate product registration; Primaquine may qualify for an accelerated or abridged review pathway as a WHO Essential Medicine with established international safety/efficacy data
PCP indication strategy: Define target patient populations (HIV patients with CD4 < 200, solid organ transplant recipients, haematology patients on immunosuppression) and document local PCP epidemiology to support PCP indication registration alongside the primary malaria indication
Pharmacovigilance program: Establish mandatory adverse event reporting for hemolytic events, methemoglobinemia, and treatment failures from first registration date
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.